For example, numerous small molecular inhibitors as monotherapy or in combination with chemotherapy, including Fms-like tyrosine kinase 3 (FLT-3) inhibitor (sorafenib), farnesyl-transferase inhibitor (tipifarnib), histone deacetylase inhibitor (vorinostat), as well as DNA methyltransferase inhibitors (decitabine, azacitidine), are already on clinical trial for AML [4,5]. Here, FLT3 is linked to acute myeloid leukemia.